Huons Biopharma Secures Product Approval for Botulinum Toxin in Kuwait

First Entry into the GCC Market

Huons Biopharma, a subsidiary of Huons Global, has officially entered the Middle Eastern market by obtaining product approval for its type A botulinum toxin preparation in Kuwait.

On May 8, Huons Biopharma announced that it had recently received product approval from the Ministry of Health Kuwait (MOH Kuwait) for 100 units of its botulinum toxin product 'Hutox' (marketed as Liztox in Korea).

Huons Biopharma secured this approval through its partnership with the local collaborator 'Al Reyada' in Kuwait. This marks the company's first entry into a Gulf Cooperation Council (GCC) country, and is expected to serve as a foothold for expanding into the broader Middle East and Gulf regional markets.

Kuwait is known as a market with strong demand for cosmetic and aesthetic procedures among GCC countries. The botulinum toxin market continues to grow, driven by increasing demand from high-income consumers and the expansion of non-invasive cosmetic treatments. In particular, the market is expanding around dermatology and aesthetic clinics, making Kuwait a strategically important country.

Building on this approval in Kuwait, Huons Biopharma plans to expand its reach across the entire Middle Eastern market, including the six GCC countries: United Arab Emirates (UAE), Saudi Arabia, Qatar, Oman, and Bahrain. The company also aims to strengthen its global market competitiveness by establishing approval strategies and quality management systems tailored to each country's regulatory requirements.

To date, Huons Biopharma has obtained product approvals in 16 countries worldwide, setting itself on a path of stable export growth. In January, the company received product approval from the National Medical Products Administration (NMPA) of China, opening the door to full-scale exports to China. Currently, Huons Biopharma is accelerating its global expansion by smoothly advancing approval procedures in major emerging markets such as Central and South America, Southeast Asia, and the Middle East.

Lee Jeonghee, CEO of Huons Biopharma, said, "With this product approval in Kuwait, Huons Biopharma has once again demonstrated its ability to meet global regulatory standards and its product competitiveness. We will continue to strengthen our influence in the global market by securing additional approvals and expanding supply in the GCC and Middle Eastern regions."

This content was produced with the assistance of AI translation services.